4//SEC Filing
Saad Mark E 4
Accession 0000950170-24-105616
CIK 0001579428other
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 7:00 PM ET
Size
9.7 KB
Accession
0000950170-24-105616
Insider Transaction Report
Form 4
Saad Mark E
Director
Transactions
- Exercise/Conversion
Common Stock
2024-09-11$3.67/sh+11,016$40,429→ 21,018 total - Sale
Common Stock
2024-09-11$91.31/sh−11,016$1,005,871→ 10,002 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-11−11,016→ 0 totalExercise: $3.67From: 2015-09-16Exp: 2024-09-16→ Common Stock (11,016 underlying)
Holdings
- 300(indirect: See explanation 5 below.)
Common Stock
Footnotes (5)
- [F1]Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this month.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $90.25 and $92.90.
- [F5]Represents additional shares held indirectly by the Reporting Person prior to September 11, 2024 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.
Documents
Issuer
Axsome Therapeutics, Inc.
CIK 0001579428
Entity typeother
Related Parties
1- filerCIK 0001295913
Filing Metadata
- Form type
- 4
- Filed
- Sep 10, 8:00 PM ET
- Accepted
- Sep 11, 7:00 PM ET
- Size
- 9.7 KB